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vention to improve treatment guideline adherence would increase compliance
with recommendations.
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OBJECTIVES: In Argentina, the public health system is deeply decentralized and
organized mainly at the provincial level. In this context, differences regarding
income distribution and access to health services require the creation of regulatory
devices and State intervention. One of the answers provided by the Buenos Aires
Health Ministry was the creation of Provincial Public Health Insurance. This pro-
gram included an innovative mechanism of human resources payment for the
public sector– a capitated system with the possibility to generate a plus over the
fixed salary- and aimed to reach the coverage of 2.4 million of citizens. The object
of this research is to analyze the performance of the strategy in terms of focaliza-
tion and development of preventive tasks associated to a higher quality at the
primary healthcare level.METHODS: A database of 1.7 million of consultations in
59 municipalities during the period 2004 to 2006 was analyzed, considering the
evolution of preventive and curative consultations. Logistic regression models
were implemented to determine the variables conditioning those tendencies.
RESULTS: The programwas appropriately focalized in poormunicipalities. Preven-
tive consultations increased 107% during the three-year period, and curative con-
sultations decreased by 56%. Preventive consultations were significantly associ-
atedwith young and female patients, as well as younger physicians. Also, poor and
populatedmunicipalities showed high associations with preventive consultations.
Differences between municipalities were relevant, showing significant associa-
tions on both signs. CONCLUSIONS: The insurance’s hiring and payment mecha-
nisms, result to be innovative and successful in the context of public health sub-
sector, conditioning the professionals to increase their efforts towards higher
quality preventive care. The strategymight be seen as one of the instruments with
the potential to enhance care quality and performance. Nevertheless, municipali-
ties show particular characteristics regarding their management and administra-
tive structures that affect the success of the program.
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OBJECTIVES: European payers are facing high levels of uncertainty about the value
of innovative drugs and their budget impact. These uncertainties are related to
both the drug’s actual usage such as dosing requirements as well as external fac-
tors such as patients’ clinical response and drug’s relative effectiveness. Over the
years, pricing schemes have been proposed to increase budget predictability. Due
to the varying perceptions of attractiveness, these schemes are not similarly ad-
opted across Europe. The research assessed the attractiveness of various schemes
as a way to reduce budget impact uncertainties and improve patient access to
innovative high priced drugs. METHODS: Both primary and secondary research
was conducted. The secondary research of published data, such as payers’ assess-
ments of pricing schemes and countries’ past policies allowed us to develop a
framework to understand the relative weights of the factors affecting payers’ un-
certainty regarding innovative-high priced drugs. The framework was then vali-
dated through qualitative primary research. RESULTS: The results revealed payers’
preference towards the cost per cycle proposition, because of its ease of implemen-
tation. Nevertheless, of the countries examined, only the UK and Italy were expe-
rienced with pricing schemes. Few others appeared to be relatively open to
schemes, sometimes at the local level and/or when more traditional approaches
are present.Most countrieswere very resistant to pricing schemes, primarily due to
the perceived complexity of schemes management and the transparency associ-
ated with it. Respondents’ opinions regarding pricing schemes also varied in terms
of the line of therapy they are targeted to. CONCLUSIONS: The heterogeneity of
Europemakes it difficult to have one scheme fit all. Schemes can reduce uncertain-
ties associated with therapy outcomes and budgetary expenditures; however pay-
ers are not willing to take additional risks associated with pricing schemes for
innovative high price drugs and prefer traditional straight discounts.
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OBJECTIVES: As a consequence of the sweeping reforms in 2010 Kazakhstan has
introduced newly Unified National Health System (UNHS), which aims at improv-
ing the health of citizens through free choice of doctors andmedical organizations,
and introduction of new financial models and economic incentives for health care
providers, among others. Within UNHS reimbursement of highly specialized med-
ical services (HSMS) is based on increased tariffs. According to Law of Kazakhstan,
HSMS are services provided using new (high) health technologies. Objectives for
the paper were to review current condition of HSMS in the country, to identify
problems and to provide appropriate recommendations to meet needs of evolving
UNHS.METHODS: Retrospective analysis of health services provided by Secondary
care regional medical centers (Regional centers) (n848) and Republican level ter-
tiary care medical centers (Republican center) (n22) over 10 months in 2010, re-
view of regulatory documents related to HSMS. RESULTS: 6% of Regional centers
and 59% of Republican centers provide HSMS. Only 12% of case mix of Republican
center is HSMS. A list of HSMS technologies that is approved by Ministry of Health
mostly consists of surgery protocols (94%). There are no clear criteria to define
HSMS. Republican centers have transferred 37 high technologies to Regional
centers. CONCLUSIONS: Introduction of UNHS created a base for competitive en-
vironment in Kazakh Healthcare system. First time in a history, Regional centers
have started to provide HSMS and Republican centers report about significant de-
cline in a number of patients that need HSMS and reduction of waiting list. As a
result, an access of Kazakh population to HSMS has improved. These findings have
shown an urgent need for health technology assessment methodology and tools,
as it helps to define truly effective health technology and to manage scarce gov-
ernment budget for health services.
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OBJECTIVES: The purpose of this study was to: 1) measure the incidence of pre-
scription problems that require pharmacist intervention; 2) determine the types
and relative frequency of prescription conveyance which contain problems that
require pharmacist intervention; and 3) estimate the pharmacy personnel time and
related practice expenses for prescriptions requiring intervention.METHODS: This
prospective study utilized an adaptation of the medication therapy intervention
(MTI) data collection form. Data were collected at two chain grocery store pharma-
cies by directly observing pharmacists for 3weeks, during the hours of 9am to 6pm.
Information recorded with each intervention included the type of prescription,
medication in question, reasons for intervention, intervention outcome, and time
spent performing intervention. Chi square analysis was conducted to compare
percentage of intervention rates between prescription conveyances. Kruskal-Wal-
lis rank test was utilized to compare the time on task values for the interventions.
Poisson regressionwas used in order to determine if significant differences existed
among the total number of interventions per group. RESULTS: Pharmacists re-
viewed 1678 new prescriptions and intervened on 157 (9.4%) over a 13 day period. A
total of 12 hours and 11 minutes was required to perform all interventions for an
overall average of 4.79 (SD0.34) minutes per intervention. Percentage of interven-
tion rates between prescription conveyances was not statistically significant
(p0.21). The time on task values for the interventions were also not statistically
significant (p0.39). However, compared with handwritten interventions, e-pre-
scribing interventions occurred 1.57 times less (p0.0001), faxed interventions oc-
curred 1.52 times less (p0.0001), and verbal interventions occurred 2.05 times less
frequently (p0.001), on average. CONCLUSIONS: E-prescribing interventions oc-
curred less frequently comparedwith handwritten interventions, whichmay pres-
ent a potential benefit. Future efforts to develop and enhance e-prescribing are
needed to add measurable value to patient care.
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OBJECTIVES: Studies published by Aetna and Health Partners have demonstrated
the value of integrated medical and pharmacy benefits in their populations. Com-
bined coverage provides the opportunity for coordinated patient outreach and
aligned policy decisions. The purpose of this analysis is to determine if integrated
benefits result in lower total medical costs when compared to plans that utilize a
carve-out pharmacy benefit.METHODS:A retrospectivematched cohort studywas
utilized in order to compare the total medical costs associated with customers in
integrated health plans with customers with a carve-out PBM. Individual custom-
ers were included if they were continuously enrolled for at least 12 months within
the same plan type, had a full set of demographic, risk, and clinical data, and were
between the ages of 18 and 65. The two groups were matched based on demo-
graphic, comorbidity, and employer characteristics. RESULTS: This analysis
matched 39,896 customers in 2007 (19,948 in each group) and 151,144 customers in
2008 (75,572 in each group) for the final analysis. Medical costs were $13.77 (p-value
0.067) and $11.39 (p-value 0.006) per customer permonth lower for customerswith an
integrated pharmacy benefit as compared to carve-out customers in 2007 and 2008
respectively. In 2007 and 2008 the bulk of the savings ($6 and $7 pcpm respectively)
were associated with lower utilization of outpatient services. CONCLUSIONS:When
controlling for demographic, clinical, and employment characteristics, there is a
significant savings associated with integrating medical and pharmacy benefits.
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DECISION MAKING IN BRAZIL BASED ON HEALTH TECHNOLOGY ASSESSMENT:
THE GOOD, THE BAD, AND THE FUTURE
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OBJECTIVES:Despite the premise of universal access supported by its Constitution,
the Brazilian healthcare system is subject to similar financing issues as in other
jurisdictions worldwide. A misunderstanding between Constitutional rights and
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